
Sidney H Kennedy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/162409/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. Cerebellum, 2023, 22, 26-36.	1.4	0
2	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.1	0
3	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	0.9	5
4	Childhood trauma and amygdala nuclei volumes in youth at risk for mental illness. Psychological Medicine, 2022, 52, 1192-1199.	2.7	22
5	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16ÂWeeks of Pharmacotherapy: A CAN-BIND Report. Cerebral Cortex, 2022, 32, 1223-1243.	1.6	6
6	Brain age in mood and psychotic disorders: a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2022, 145, 42-55.	2.2	32
7	Structuro-functional surrogates of response to subcallosal cingulate deep brain stimulation for depression. Brain, 2022, 145, 362-377.	3.7	17
8	A qualitative systematic review of neurocognition in suicide ideators and attempters: Implications for cognitive-based psychotherapeutic interventions. Neuroscience and Biobehavioral Reviews, 2022, 132, 92-109.	2.9	12
9	"One Degree of Separation― A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. Canadian Journal of Psychiatry, 2022, , 070674372110706.	0.9	6
10	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. Journal of Affective Disorders, 2022, 300, 50-58.	2.0	3
11	Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis. Schizophrenia Research, 2022, 240, 220-227.	1.1	6
12	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	1.3	3
13	Habenular Involvement in Response to Subcallosal Cingulate Deep Brain Stimulation for Depression. Frontiers in Psychiatry, 2022, 13, 810777.	1.3	7
14	Investigating the Effects of Auditory and Vibrotactile Rhythmic Sensory Stimulation on Depression: An EEG Pilot Study. Cureus, 2022, 14, e22557.	0.2	3
15	Biophysical compartment models for single-shell diffusion MRI in the human brain: a model fitting comparison. Physics in Medicine and Biology, 2022, 67, 055009.	1.6	1
16	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior, 2022, 12, e2555.	1.0	3
17	Nitrous oxide for the treatment of psychiatric disorders: A systematic review of the clinical trial landscape. Acta Psychiatrica Scandinavica, 2022, 146, 126-138.	2.2	6
18	Beyond Response: Aiming for Quality Remission in Depression. Advances in Therapy, 2022, 39, 20-28.	1.3	4

19 Palm severity and pain interference during major depressive episodes treated with escitalopram and arpiprazole adjunctive therapy: a CAN-BIND-1 report. Psychiatry Research, 2022, 312, 114557. 1.7 1 20 Neurochemical Alterations in Social Anxiety Disorder (SAD): A Systematic Review of Proton Magnetic Resonance Spectroscopic Studies. International Journal of Molecular Sciences, 2022, 23, 4754. 1.8 4 21 P256, ABCB1 Cene Variants and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis Including Results From the CAN-BIND-1 Cohort. Biological Psychiatry, 2022, 91, S191. 0.7 1 22 P382, Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Org. 0.7 1 23 Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder. A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613. 2.0 1 24 Intrinsic Connectivity Networks of Clutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, . 1.3 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders, Reports, 2022, 313, 235-242. 2.0 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI 2.0 0 27 Define and charact	ITATIONS
20 Resonance Spectroscopic Studies. International Journal of Molecular Sciences, 2022, 23, 4754. 1.8 4 21 P256. ABCB1 Cene Variants and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis Including Results From the CAN-BIND-1 Cohort. Biological Psychiatry, 2022, 91, S191. 0.7 0 22 P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242. 0.7 1 23 Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613. 2.0 1 24 Intrinsic Connectivity Networks of Clutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, . 1.3 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 0 0 28 Acute and chronic stress predi	
21 Meta-Analysis Including Results From the CAN-BIND-1 Cohort. Biological Psychiatry, 2022, 91, S191. 0.7 0 22 P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242. 0.7 1 23 Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613. 2.0 1 24 Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, . 1.3 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal or Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. 2.0 0 29 Clinical staging for youth atã@risk fo	
22 Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242. 0.7 1 23 Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613. 2.0 1 24 Intrinsic Connectivity Networks of Clutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, . 1.3 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 235-242. 0.0 0 29 Clinical staging for youth atâGisk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196. 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND stud	
23 depressive disorder: A CAN-BiND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613. 2.0 1 24 Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. Frontiers in Psychiatry, 2022, 13, . 1.3 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. 0.9 6 29 Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196. 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. 2.5 11 31 A clinical approach to treatment resistance in depressed patients:	
24 Review. Frontiers in Psychiatry, 2022, 13, . 11 12 13 12 25 Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 0 29 Clinical staging for youth atâCrisk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196. 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. 2.5 11 a. A clinical approach to treatment resistance in depressed patients: What to do when the usual 1.0 0.0	
23 of Affective Disorders Reports, 2022, 9, 100370. 0.9 0 26 Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. 2.0 0 29 Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. 2.5 11 a A clinical approach to treatment resistance in depressed patients: What to do when the usual 1.0 0	2
26 in a multi-site sample: A CAN-BIND-1 report. Neurolmage: Clinical, 2022, 35, 103120. 1.4 8 27 Define and characterize the anhedonia in major depressive disorder: An explorative study. Journal of Affective Disorders, 2022, 313, 235-242. 2.0 4 28 Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. 2.0 0 29 Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196. 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. 2.5 11 au A clinical approach to treatment resistance in depressed patients: What to do when the usual 1.4 0.9	
 Affective Disorders, 2022, 313, 235-242. Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study A clinical approach to treatment resistance in depressed patients: What to do when the usual 	
28 depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14. 2.0 0 29 Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial 0.9 6 30 Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. 2.5 11 at A clinical approach to treatment resistance in depressed patients: What to do when the usual 1.8 90	
 Biotechnology, 2021, 15, 1188-1196. Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194. A clinical approach to treatment resistance in depressed patients: What to do when the usual 	
A clinical approach to treatment resistance in depressed patients: What to do when the usual	
	L
	2
32 Substance use in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2021, 15, 634-641. 0.9 1	
Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy. Annals of 2.8 68 Neurology, 2021, 89, 426-443.	8
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe 34 De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concerœnt 54 L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Canadian Journal of Psychiatry, 2021, 66, 113-125.	4
Personality and risk for serious mental illness. Microbial Biotechnology, 2021, 15, 133-139. 0.9 5	

#	Article	IF	CITATIONS
37	Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2021, 66, 418-420.	0.9	1
38	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	2.4	22
39	Treatmentâ€resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depression and Anxiety, 2021, 38, 456-467.	2.0	38
40	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. Frontiers in Psychiatry, 2021, 12, 617997.	1.3	32
41	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs, 2021, 35, 291-304.	2.7	4
42	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. Pharmacopsychiatry, 2021, 54, 225-231.	1.7	1
43	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs, 2021, 35, 439-450.	2.7	4
44	Investigating correlates of athletic identity and sport-related injury outcomes: a scoping review. BMJ Open, 2021, 11, e044199.	0.8	23
45	â€`Distant socializing,' not â€`social distancing' as a public health strategy for COVID-19. Pathogens and Global Health, 2021, 115, 357-364.	1.0	8
46	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CANâ€BIND 1 report. Personality and Mental Health, 2021, 15, 273-282.	0.6	1
47	Symptom dimensions of major depression in a large community-based cohort. Psychological Medicine, 2021, , 1-8.	2.7	3
48	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. Psychiatry Research - Neuroimaging, 2021, 312, 111289.	0.9	4
49	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS ONE, 2021, 16, e0253023.	1.1	4
50	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. Communications Biology, 2021, 4, 903.	2.0	16
51	Exploring brain connectivity changes in major depressive disorder using <scp>functionalâ€structural</scp> data fusion: A CANâ€BINDâ€1 study. Human Brain Mapping, 2021, 42, 4940-4957.	1.9	8
52	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	2.4	3
53	Neuron-derived extracellular vesicles enriched from plasma show altered size and miRNA cargo as a function of antidepressant drug response. Molecular Psychiatry, 2021, 26, 7417-7424.	4.1	45
54	Association between the expression of IncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. Translational Psychiatry, 2021, 11, 469.	2.4	1

#	Article	IF	CITATIONS
55	Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape. Brain Stimulation, 2021, 14, 1393-1403.	0.7	14
56	Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia. Journal of Affective Disorders, 2021, 293, 1-8.	2.0	12
57	Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study. Journal of Psychiatric Research, 2021, 142, 321-327.	1.5	1
58	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	1.3	8
59	A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. Brain Stimulation, 2021, 14, 1447-1455.	0.7	27
60	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. Journal of Affective Disorders, 2021, 295, 1095-1101.	2.0	7
61	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. NeuroImage: Clinical, 2021, 32, 102864.	1.4	13
62	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	2.7	38
63	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.1	32
64	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1. Canadian	0.9	0
65	Journal of Psychiatry, 2021, 66, 798-806. Stellate Ganglion Block for Psychiatric Disorders: A Systematic Review of the Clinical Research Landscape. Chronic Stress, 2021, 5, 247054702110551.	1.7	9
66	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. Frontiers in Neuroinformatics, 2021, 15, 622951.	1.3	2
67	Comparative study of the pencil-and-paper and digital formats of the Spanish DARS scale. Acta Neuropsychiatrica, 2021, , 1-7.	1.0	0
68	Suicide-related presentations of homeless individuals to an inner-city emergency department. General Hospital Psychiatry, 2020, 63, 5-6.	1.2	3
69	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	2.7	17
70	Social and role functioning in youth at risk of serious mental illness. Microbial Biotechnology, 2020, 14, 463-469.	0.9	8
71	Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: AÂthree-arm, blinded, randomized controlled trial. Brain Stimulation, 2020, 13, 337-340.	0.7	26
72	Sleep disturbances in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2020, 14, 373-378.	0.9	14

#	Article	IF	CITATIONS
73	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	2.8	37
74	Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICEâ€D coâ€design process. Journal of Evaluation in Clinical Practice, 2020, 26, 1259-1269.	0.9	12
75	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	2.8	49
76	Trauma in Youth At-Risk for Serious Mental Illness. Journal of Nervous and Mental Disease, 2020, 208, 70-76.	0.5	7
77	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. International Journal of Neuropsychopharmacology, 2020, 23, 88-95.	1.0	12
78	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. Journal of Affective Disorders, 2020, 264, 414-424.	2.0	6
79	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	2.0	4
80	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. Human Brain Mapping, 2020, 41, 1400-1415.	1.9	7
81	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. Biological Psychiatry, 2020, 87, S431.	0.7	1
82	Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. International Clinical Psychopharmacology, 2020, 35, 243-253.	0.9	21
83	Functional imaging in youth at risk for transdiagnostic serious mental illness: Initial results from the PROCAN study. Microbial Biotechnology, 2020, 15, 1276-1291.	0.9	3
84	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	2.8	23
85	White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. Psychiatry Research - Neuroimaging, 2020, 302, 111106.	0.9	4
86	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry, 2020, 20, 268.	1.1	16
87	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. NeuroImage: Clinical, 2020, 25, 102178.	1.4	10
88	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109867.	2.5	8
89	Aberrant limbic brain structures in young individuals at risk for mental illness. Psychiatry and Clinical Neurosciences, 2020, 74, 294-302.	1.0	14
90	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in in individuals with mood disorders. Psychiatry Research, 2020, 288, 112967.	1.7	6

#	Article	IF	CITATIONS
91	GPR56/ADGRG1 is associated with response to antidepressant treatment. Nature Communications, 2020, 11, 1635.	5.8	38
92	Childhood maltreatment and the clinical characteristics of major depressive disorder in adolescence and adulthood Journal of Abnormal Psychology, 2020, 129, 469-479.	2.0	28
93	Neuroanatomical predictors of response to subcallosal cingulate deep brain stimulation for treatment-resistant depression. Journal of Psychiatry and Neuroscience, 2020, 45, 45-54.	1.4	22
94	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	1.1	9
95	Dr Uher and Colleagues Reply. Journal of Clinical Psychiatry, 2020, 82, .	1.1	1
96	Patient Response Trajectories in Major Depressive Disorder. Psychopharmacology Bulletin, 2020, 50, 8-28.	0.0	6
97	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. Innovations in Clinical Neuroscience, 2020, 17, 30-40.	0.1	6
98	Treatment History of Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2019, 64, 145-154.	0.9	8
99	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	2.5	113
100	Integrating digital phenotyping in clinical characterization of individuals with mood disorders. Neuroscience and Biobehavioral Reviews, 2019, 104, 223-230.	2.9	38
101	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. Journal of Affective Disorders, 2019, 257, 765-773.	2.0	20
102	The utility of artificial intelligence in suicide risk prediction and the management of suicidal behaviors. Australian and New Zealand Journal of Psychiatry, 2019, 53, 954-964.	1.3	56
103	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Network Open, 2019, 2, e1913304.	2.8	19
104	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	2.4	33
105	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 913-924.	1.1	21
106	T97. Predicting Functioning and Quality of Life Using Objective and Subjective Measures of Sleep and Biological Rhythms in Major Depressive and Bipolar Disorder. Biological Psychiatry, 2019, 85, S166.	0.7	0
107	F130. Subfield-Specific Hippocampal Volumes in Youth at Risk for Mental Illness. Biological Psychiatry, 2019, 85, S263-S264.	0.7	0
108	Clinical staging for youth atâ€risk for serious mental illness. Microbial Biotechnology, 2019, 13, 1416-1423.	0.9	42

#	Article	IF	CITATIONS
109	A Pilot Study Investigating the Effect of Music-Based Intervention on Depression and Anhedonia. Frontiers in Psychology, 2019, 10, 1038.	1.1	17
110	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. NeuroImage, 2019, 197, 589-597.	2.1	24
111	The symptomâ€specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data metaâ€analysis. World Psychiatry, 2019, 18, 183-191.	4.8	68
112	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S254.	0.7	0
113	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. Biological Psychiatry, 2019, 85, S344-S345.	0.7	0
114	The impact of comorbid pain and depression in the United States: results from a nationally representative survey. Scandinavian Journal of Pain, 2019, 19, 319-325.	0.5	23
115	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	1.3	20
116	Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study. American Journal of Psychiatry, 2019, 176, 367-375.	4.0	93
117	Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 683-696.	1.3	48
118	Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microbial Cell, 2019, 6, 454-481.	1.4	161
119	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	2.7	22
120	Spanish adaptation of the Dimensional Anhedonia Rating Scale (DARS). Journal of Affective Disorders, 2019, 245, 702-707.	2.0	13
121	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	1.4	37
122	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	61
123	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	1.1	16
124	More data, more answers: picking the optimal antidepressant. Lancet, The, 2018, 391, 1333-1334.	6.3	6
125	Improvements in Health-Related Quality of Life With Electroconvulsive Therapy. Journal of ECT, 2018, 34, 87-94.	0.3	22
126	Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions. Current Psychiatry Reports, 2018, 20, 13.	2.1	26

8

#	Article	IF	CITATIONS
127	Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neuroscience and Therapeutics, 2018, 24, 615-623.	1.9	92
128	Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet, The, 2018, 391, 1683-1692.	6.3	706
129	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. Journal of Psychiatric Research, 2018, 99, 62-68.	1.5	60
130	Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management. CNS Drugs, 2018, 32, 65-74.	2.7	44
131	Abnormal Functional Connectivity of Frontopolar Subregions in Treatment-Nonresponsive Major Depressive Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 337-347.	1.1	15
132	Unpacking Major Depressive Disorder: From Classification to Treatment Selection. Canadian Journal of Psychiatry, 2018, 63, 308-313.	0.9	12
133	Relative shortâ€ŧerm efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Human Psychopharmacology, 2018, 33, e2646.	0.7	2
134	Anhedonia as a Crucial Factor of Depression: Assessment, Neurobiological Underpinnings and Treatment. , 2018, , 99-112.		1
135	222. Clinical Results From the Theta Burst Versus High Frequency Repetitive Transcranial Magnetic Stimulation Effectiveness Evaluation in Depression (THREE-D) Randomized Non-Inferiority Trial. Biological Psychiatry, 2018, 83, S89.	0.7	0
136	Conflict monitoring mechanism at the single-neuron level in the human ventral anterior cingulate cortex. NeuroImage, 2018, 175, 45-55.	2.1	13
137	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.1	1,079
138	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics Journal, 2018, 18, 406-412.	0.9	17
139	Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. Brain Stimulation, 2018, 11, 181-189.	0.7	39
140	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	1.3	32
141	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. Journal of Affective Disorders, 2018, 226, 294-300.	2.0	7
142	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	2.0	59
143	Editorial. Current Opinion in Psychiatry, 2018, 31, 1-2.	3.1	1
144	Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. Journal of Affective Disorders, 2018, 233, 21-35.	2.0	124

#	Article	IF	CITATIONS
145	Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. Journal of Affective Disorders, 2018, 225, 54-63.	2.0	31
146	Report of the 2016 Mental Health Expert Panel on suicide prevention in the Canadian Armed Forces. Journal of Military, Veteran and Family Health, 2018, 4, 70-89.	0.3	8
147	Neurocognitive deficits in a transdiagnostic clinical staging model. Psychiatry Research, 2018, 270, 1137-1142.	1.7	17
148	Family functioning in youth at-risk for serious mental illness. Comprehensive Psychiatry, 2018, 87, 17-24.	1.5	16
149	Vagus Nerve Stimulation: A Treatment in Evolution. Cognitive and Behavioral Neurology, 2018, 31, 99-100.	0.5	0
150	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. Focus (American Psychiatric Publishing), 2018, 16, 85-94.	0.4	12
151	Youth at-risk for serious mental illness: methods of the PROCAN study. BMC Psychiatry, 2018, 18, 219.	1.1	29
152	224. Resting-State fMRI Predictors and Mechanisms of rTMS Treatment Response: Neuroimaging Results of the Three-D Study. Biological Psychiatry, 2018, 83, S90.	0.7	0
153	Effect of agomelatine 25–50â€ ⁻ mg on functional outcomes in patients with major depressive disorder. Journal of Affective Disorders, 2018, 238, 122-128.	2.0	15
154	Is tetraethyl lead poison affecting contemporary indigenous suicides in Ontario, Canada?. Psychiatry Research, 2017, 251, 253-254.	1.7	3
155	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	0.9	0
156	Oral Ketamine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2017, 37, 464-467.	0.7	26
157	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. Canadian Journal of Psychiatry, 2017, 62, 353-354.	0.9	0
158	The Efficacy of Psychostimulants in Major Depressive Episodes. Journal of Clinical Psychopharmacology, 2017, 37, 412-418.	0.7	56
159	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	5.8	144
160	Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. International Journal of Neuropsychopharmacology, 2017, 20, 619-623.	1.0	48
161	A pilot, openâ€label, 8â€week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disorders, 2017, 19, 198-213.	1.1	39
162	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. Journal of Affective Disorders, 2017, 210, 57-65.	2.0	42

#	Article	IF	CITATIONS
163	The Default Mode Network in Healthy Individuals: A Systematic Review and Meta-Analysis. Brain Connectivity, 2017, 7, 25-33.	0.8	240
164	Sirukumab: A Potential Treatment for Mood Disorders?. Advances in Therapy, 2017, 34, 78-90.	1.3	44
165	751. The Role of Childhood Maltreatment in Depression: Overview of the Literature and Insights from the CAN-BIND Program. Biological Psychiatry, 2017, 81, S304-S305.	0.7	0
166	754. Inflammatory Markers as Mediators of the Association between Early Life Adversity and Hippocampal Volume in Adult Patients with depression: Findings from Phase 1 of the CAN-BIND Study. Biological Psychiatry, 2017, 81, S306.	0.7	0
167	753. The Influence of Early Life Trauma on Epigenetic Markers in a CAN-BIND Sample of Responders and Non-Responders to Escitalopram. Biological Psychiatry, 2017, 81, S305-S306.	0.7	0
168	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Scientific Reports, 2017, 7, 7473.	1.6	28
169	Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology, 2017, 31, 312-319.	2.0	15
170	Brexpiprazole in the Treatment of Major Depressive Disorder. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1773180.	0.4	5
171	Neuroimaging tests for clinical psychiatry: Are we there yet?. Journal of Psychiatry and Neuroscience, 2017, 42, 219-221.	1.4	2
172	Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation. Frontiers in Human Neuroscience, 2017, 11, 74.	1.0	30
173	Recognition and management of antidepressant discontinuation syndrome. Journal of Psychiatry and Neuroscience, 2017, 42, E7-E8.	1.4	11
174	Functional Recovery in Major Depressive Disorder. primary care companion for CNS disorders, The, 2016, 18, .	0.2	51
175	Ketamine: stimulating antidepressant treatment?. BJPsych Open, 2016, 2, e5-e9.	0.3	24
176	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectrums, 2016, 21, 362-366.	0.7	31
177	Admixture analysis of age at onset in first episode bipolar disorder. Journal of Affective Disorders, 2016, 201, 88-94.	2.0	14
178	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 506-509.	0.9	58
179	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	0.9	165
180	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 510-523.	0.9	209

#	Article	IF	CITATIONS
181	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	0.9	746
182	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	0.9	340
183	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 561-575.	0.9	415
184	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 576-587.	0.9	227
185	Zebrafish models of major depressive disorders. Journal of Neuroscience Research, 2016, 94, 3-14.	1.3	48
186	Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. Molecular Neuropsychiatry, 2016, 2, 1-14.	3.0	47
187	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	1.1	114
188	Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. European Neuropsychopharmacology, 2016, 26, 378-389.	0.3	36
189	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. Obesity Research and Clinical Practice, 2016, 10, 531-543.	0.8	20
190	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. American Journal of Psychiatry, 2016, 173, 481-490.	4.0	41
191	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Therapeutic Advances in Chronic Disease, 2016, 7, 153-159.	1.1	35
192	Assessing anhedonia in depression: Potentials and pitfalls. Neuroscience and Biobehavioral Reviews, 2016, 65, 21-35.	2.9	344
193	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. Innovations in Clinical Neuroscience, 2016, 13, 20-31.	0.1	11
194	MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder. Journal of Visualized Experiments, 2015, , e53129.	0.2	17
195	STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!. Canadian Journal of Psychiatry, 2015, 60, 6-8.	0.9	4
196	Depression and Employment Status in Primary and Tertiary Care Settings. Canadian Journal of Psychiatry, 2015, 60, 14-22.	0.9	59
197	rTMS of the Dorsomedial Prefrontal Cortex for Major Depression: Safety, Tolerability, Effectiveness, and Outcome Predictors for 10ÂHz Versus Intermittent Theta-burst Stimulation. Brain Stimulation, 2015, 8, 208-215.	0.7	217
198	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opinion on Investigational Drugs, 2015, 24, 459-475.	1.9	41

#	Article	IF	CITATIONS
199	The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2015, 16, 45-56.	1.3	28
200	Paired Pulse Depression in the Subcallosal Cingulate Region of Depression Patients. Biological Psychiatry, 2015, 78, e3-e4.	0.7	7
201	Deep Brain Stimulation Modulates Gamma Oscillations and Theta–Gamma Coupling in Treatment Resistant Depression. Brain Stimulation, 2015, 8, 1033-1042.	0.7	47
202	Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia. Journal of Affective Disorders, 2015, 187, 101-105.	2.0	19
203	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. JAMA Psychiatry, 2015, 72, 1102.	6.0	155
204	Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. Psychiatry Research, 2015, 229, 109-119.	1.7	111
205	Evidence to support peripheral and central IL-6 signaling targets to treat depression. Expert Opinion on Investigational Drugs, 2015, 24, 991-992.	1.9	1
206	Genetic variation in <i>IL-1β, IL-2, IL-6, TSPO</i> and <i>BDNF</i> and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics, 2015, 16, 1919-1929.	0.6	19
207	The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. Comprehensive Psychiatry, 2015, 56, 279-282.	1.5	123
208	The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier―in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. Journal of Affective Disorders, 2015, 172, 259-264.	2.0	96
209	Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Annals of Clinical Psychiatry, 2015, 27, 142-9.	0.6	37
210	EEG Power Asymmetry and Functional Connectivity as a Marker of Treatment Effectiveness in DBS Surgery for Depression. Neuropsychopharmacology, 2014, 39, 1270-1281.	2.8	86
211	Resting-State Cortico-Thalamic-Striatal Connectivity Predicts Response to Dorsomedial Prefrontal rTMS in Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 488-498.	2.8	241
212	GENDER AS PREDICTOR AND MODERATOR OF OUTCOME IN COGNITIVE BEHAVIOR THERAPY AND PHARMACOTHERAPY FOR ADULT DEPRESSION: AN "INDIVIDUAL PATIENT DATA―META-ANALYSIS. Depression and Anxiety, 2014, 31, 941-951.	n2.0	122
213	Anhedonia and Reward-Circuit Connectivity Distinguish Nonresponders from Responders to Dorsomedial Prefrontal Repetitive Transcranial Magnetic Stimulation in Major Depression. Biological Psychiatry, 2014, 76, 176-185.	0.7	281
214	Neuromodulation for treatment-refractory major depressive disorder. Cmaj, 2014, 186, 33-39.	0.9	35
215	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial. Psychiatry Research, 2014, 220, 245-250.	1.7	45
216	Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study. Journal of Affective Disorders, 2014, 166, 139-143.	2.0	5

#	Article	IF	CITATIONS
217	A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25–50mg) in patients with major depressive disorder. European Neuropsychopharmacology, 2014, 24, 553-563.	0.3	26
218	Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment. Canadian Journal of Psychiatry, 2014, 59, 649-654.	0.9	276
219	Treatment-Resistant Depression in Primary Care across Canada. Canadian Journal of Psychiatry, 2014, 59, 349-357.	0.9	120
220	Predictors of Response to Adjunctive Osmotic-Release Methylphenidate or Placebo in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2014, 34, 755-759.	0.7	16
221	Review of Evidence for Use of Antidepressants in Bipolar Depression. primary care companion for CNS disorders, The, 2014, 16, .	0.2	12
222	Agomelatine in Depressive Disorders. , 2014, , 275-279.		0
223	SSRIs and Related Compounds. , 2014, , 1-7.		0
224	The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders. Advances in Therapy, 2013, 30, 671-683.	1.3	3
225	Comments on the Use of Agomelatine in the Treatment of Depressive Disorder According to Clinical Guidelines in Colombia. Revista Colombiana De PsiquiatrÃa, 2013, 42, 356-357.	0.1	0
226	The cardiovascular safety profile of escitalopram. European Neuropsychopharmacology, 2013, 23, 1391-1400.	0.3	43
227	The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder. Journal of Sexual Medicine, 2013, 10, 2465-2476.	0.3	47
228	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. Journal of Affective Disorders, 2013, 151, 573-581.	2.0	48
229	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.1	740
230	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.1	14
231	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.1	1
232	Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Human Psychopharmacology, 2013, 28, 151-159.	0.7	207
233	The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Human Psychopharmacology, 2013, 28, 421-427.	0.7	22
234	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. British Journal of Psychiatry, 2013, 203, 358-365.	1.7	47

#	Article	IF	CITATIONS
235	Management strategies for SSRIinduced sexual dysfunction. Journal of Psychiatry and Neuroscience, 2013, 38, E27-E28.	1.4	13
236	A Review of Antidepressant Therapy in Primary Care. primary care companion for CNS disorders, The, 2013, 15, .	0.2	26
237	A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. Journal of Neurosurgery, 2012, 116, 315-322.	0.9	319
238	Monoamine Oxidase Inhibitors Potentiate the Effects of Deep Brain Stimulation. American Journal of Psychiatry, 2012, 169, 1320-1321.	4.0	19
239	The Association between Childhood Adversity and Components of Metabolic Syndrome in Adults with Mood Disorders: Results from the International Mood Disorders Collaborative Project. International Journal of Psychiatry in Medicine, 2012, 43, 165-177.	0.8	67
240	The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction. Current Pharmaceutical Design, 2012, 18, 5976-5989.	0.9	61
241	Editorial. Journal of Neurosurgery, 2012, 116, 313-314.	0.9	3
242	Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder Journal of Consulting and Clinical Psychology, 2012, 80, 342-353.	1.6	74
243	Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behavioural Brain Research, 2012, 235, 302-317.	1.2	162
244	The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. European Psychiatry, 2012, 27, 223-228.	0.1	96
245	A randomized, doubleâ€blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disorders, 2012, 14, 697-706.	1.1	81
246	Emerging drugs for major depressive disorder: an update. Expert Opinion on Emerging Drugs, 2012, 17, 285-294.	1.0	10
247	Admixture analysis of age at onset in major depressive disorder. General Hospital Psychiatry, 2012, 34, 686-691.	1.2	19
248	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 803-810.	1.1	111
249	Why are there no treatment guidelines for mood disorders and comorbidities?. Annals of Clinical Psychiatry, 2012, 24, 4-5.	0.6	25
250	Instruments to measure sexual dysfunction in community and psychiatric populations. Journal of Psychosomatic Research, 2011, 70, 99-109.	1.2	36
251	Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets. Journal of Affective Disorders, 2011, 132, S21-S28.	2.0	17
252	The keys to improving depression outcomes. European Neuropsychopharmacology, 2011, 21, S694-S702.	0.3	10

#	Article	IF	CITATIONS
253	Weight Loss Following Roux-en-Y Gastric Bypass Surgery: A Systematic Review of Psychosocial Predictors. Current Psychiatry Reviews, 2011, 7, 226-233.	0.9	15
254	A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. International Clinical Psychopharmacology, 2011, 26, 151-158.	0.9	15
255	Assessing the â€ [~] true' effect of active antidepressant therapy <i>v.</i> placebo in major depressive disorder: use of a mixture model. British Journal of Psychiatry, 2011, 199, 501-507.	1.7	65
256	Association of the Malnutrition-Inflammation Score With Clinical Outcomes in Kidney Transplant Recipients. American Journal of Kidney Diseases, 2011, 58, 101-108.	2.1	70
257	Improving the clinical effectiveness of antidepressant treatment. Journal of Affective Disorders, 2011, 132, S1-S2.	2.0	0
258	Barriers to achieving treatment goals: A focus on sleep disturbance and sexual dysfunction. Journal of Affective Disorders, 2011, 132, S14-S20.	2.0	19
259	Association between the Malnutrition–Inflammation Score and depressive symptoms in kidney transplanted patients. General Hospital Psychiatry, 2011, 33, 157-165.	1.2	31
260	Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus. NeuroMolecular Medicine, 2011, 13, 93-116.	1.8	135
261	Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions. Current Psychiatry Reports, 2011, 13, 316-320.	2.1	50
262	The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology, 2011, 26, 537-542.	0.7	45
263	Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation. International Review of Psychiatry, 2011, 23, 424-436.	1.4	31
264	Deep Brain Stimulation for Treatment-Resistant Depression: Follow-Up After 3 to 6 Years. American Journal of Psychiatry, 2011, 168, 502-510.	4.0	453
265	Omega-3 Supplements in Pregnancy: Are We Too Late to Identify the Possible Benefits?. Journal of Obstetrics and Gynaecology Canada, 2010, 32, 209-216.	0.3	1
266	Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps. Focus (American Psychiatric) Tj ETQq0 0 0 rgE	BT /Overloo	ck 10 Tf 50 22
267	A Comparison of Desipramine Response in Younger and Older Women. Journal of Clinical Psychopharmacology, 2010, 30, 80-82.	0.7	2
268	Frequency and Correlates of Gambling Problems in Outpatients with Major Depressive Disorder and Bipolar Disorder. Canadian Journal of Psychiatry, 2010, 55, 568-576.	0.9	44
269	Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?. Advances in Therapy, 2010, 27, 63-80.	1.3	69
270	The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Advances in	1.3	33

Therapy, 2010, 27, 828-836.

33

#	Article	IF	CITATIONS
271	The Relationship between Testosterone and Sexual Function in Depressed and Healthy Men. Journal of Sexual Medicine, 2010, 7, 816-825.	0.3	38
272	Flibanserin: Initial Evidence of Efficacy on Sexual Dysfunction, in Patients with Major Depressive Disorder. Journal of Sexual Medicine, 2010, 7, 3449-3459.	0.3	39
273	Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disorders, 2010, 12, 691-701.	1.1	24
274	Harm Avoidance as a Mediator of Treatment Response to Antidepressant Treatment of Patients with Major Depression. Psychotherapy and Psychosomatics, 2010, 79, 116-122.	4.0	32
275	The Association between Conventional Antidepressants and the Metabolic Syndrome. CNS Drugs, 2010, 24, 741-753.	2.7	73
276	The Nature and Treatment of Therapy-Resistant Depression. Modern Problems of Pharmacopsychiatry, 2010, , 243-253.	2.5	0
277	Agomelatine in the Treatment of Major Depressive Disorder. CNS Drugs, 2010, 24, 479-499.	2.7	121
278	Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Current Medical Research and Opinion, 2010, 26, 2643-2651.	0.9	5
279	Attention-Deficit/Hyperactivity Disorder in Adults With Bipolar Disorder or Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, .	0.6	54
280	Subgenual Cingulate Gyrus Deep Brain Stimulation: Current Status and Future Directions. Psychiatric Annals, 2010, 40, 485-491.	0.1	1
281	The sex effects scale: pilot validation in a healthy population. Psychopharmacology Bulletin, 2010, 43, 15-25.	0.0	12
282	Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. Evidence-Based Mental Health, 2010, 13, 89-89.	2.2	0
283	Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment, 2009, 5, 127.	1.0	14
284	Perceptions of Efficacy, Safety, and Tolerability: Impact on Evaluating New Treatments. CNS Spectrums, 2009, 14, 8-10.	0.7	0
285	Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opinion on Pharmacotherapy, 2009, 10, 3061-3075.	0.9	30
286	Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs, 2009, 14, 439-453.	1.0	27
287	Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. Journal of Neurosurgery, 2009, 111, 1209-1215.	0.9	143
288	Sex differences in hormonal responses to a social stressor in chronic major depression. Psychoneuroendocrinology, 2009, 34, 1235-1241.	1.3	66

#	Article	IF	CITATIONS
289	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S44-S53.	2.0	175
290	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S54-S64.	2.0	91
291	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S26-S43.	2.0	357
292	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders, 2009, 117, S15-S25.	2.0	154
293	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Journal of Affective Disorders, 2009, 117, S1-S2.	2.0	192
294	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders, 2009, 117, S5-S14.	2.0	128
295	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.1	545
296	CANMAT guidelines: authors' response. Bipolar Disorders, 2009, 11, 773-773.	1.1	0
297	CANMAT/ ISBD treatment guidelines: response to Shen etÂal Bipolar Disorders, 2009, 11, 775-775.	1.1	0
298	The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression?. NeuroToxicology, 2009, 30, 497-521.	1.4	83
299	Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion, 2009, 25, 161-175.	0.9	125
300	Agomelatine. CNS Drugs, 2009, 23, 41-47.	2.7	22
301	Sexual Dysfunction, Depression, and the Impact of Antidepressants. Journal of Clinical Psychopharmacology, 2009, 29, 157-164.	0.7	271
302	A Novel Examination of Atypical Major Depressive Disorder Based on Attachment Theory. Journal of Clinical Psychiatry, 2009, 70, 879-887.	1.1	21
303	Reply to Augmentation of Dopaminergic Agents for Major Depressive Disorder. Journal of Clinical Psychiatry, 2009, 70, 433-434.	1.1	0
304	Dr Levitan and Colleagues Reply. Journal of Clinical Psychiatry, 2009, 70, 1726-1727.	1.1	0
305	Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 175-80.	1.4	96
306	Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disorders, 2008, 10, 1-37.	1.1	245

#	Article	IF	CITATIONS
307	Dimensional personality traits and treatment outcome in patients with major depressive disorder. Journal of Affective Disorders, 2008, 108, 241-250.	2.0	132
308	Investigating associations between cortisol and cognitive reactivity to sad mood provocation and the prediction of relapse in remitted major depression. Asian Journal of Psychiatry, 2008, 1, 33-36.	0.9	15
309	Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression. Biological Psychiatry, 2008, 64, 461-467.	0.7	865
310	The Relationship Between Childhood Abuse and Suicidality in Adult Bipolar Disorder. Violence and Victims, 2008, 23, 361-372.	0.4	51
311	The hepatic safety profile of duloxetine: a review. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 281-285.	1.5	47
312	Deep Brain Stimulation for Treatment-Resistant Depression. Focus (American Psychiatric Publishing), 2008, 6, 143-154.	0.4	2
313	Neural Stimulation Successfully Treats Depression in Patients With Prior Ablative Cingulotomy. American Journal of Psychiatry, 2008, 165, 687-693.	4.0	58
314	Acetyl-L-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?. Expert Opinion on Investigational Drugs, 2008, 17, 827-843.	1.9	18
315	A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR. Journal of Clinical Psychopharmacology, 2008, 28, 329-333.	0.7	183
316	Datapoints: Rates and Patterns of Treatment Seeking by Individuals With Mood and Anxiety Disorders. Psychiatric Services, 2008, 59, 1099-1099.	1.1	1
317	Neuropsychological Impact of Cg25 Deep Brain Stimulation for Treatment-Resistant Depression. Journal of Nervous and Mental Disease, 2008, 196, 405-410.	0.5	126
318	Combining Mirtazapine and Duloxetine in Treatment-Resistant Depression Improves Outcomes and Sexual Function. Journal of Clinical Psychopharmacology, 2008, 28, 107-108.	0.7	14
319	Personality and Differential Treatment Response in Major Depression: A Randomized Controlled Trial Comparing Cognitive-Behavioural Therapy and Pharmacotherapy. Canadian Journal of Psychiatry, 2008, 53, 361-370.	0.9	139
320	Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience, 2008, 10, 271-277.	1.8	231
321	Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive Disorder. Journal of Clinical Psychiatry, 2008, 69, 87-94.	1.1	101
322	Neuroimaging Approaches in Mood Disorders: Technique and Clinical Implications. Annals of Clinical Psychiatry, 2007, 19, 265-277.	0.6	32
323	Review: Response to SSRIs in unipolar depression occurs in the first week of treatment. Evidence-Based Mental Health, 2007, 10, 81-81.	2.2	0
324	Comparing Features of Bipolar Disorder to Major Depressive Disorder in a Tertiary Mood Disorders Clinic. Annals of Clinical Psychiatry, 2007, 19, 313-317.	0.6	12

#	Article	IF	CITATIONS
325	Treatment Resistant Depression— Advances in Somatic Therapies. Annals of Clinical Psychiatry, 2007, 19, 279-287.	0.6	71
326	Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial. American Journal of Psychiatry, 2007, 164, 778-788.	4.0	343
327	Changes in Autobiographical Memory Specificity following Cognitive Behavior Therapy and Pharmacotherapy for Major Depression. Psychopathology, 2007, 40, 147-152.	1.1	59
328	Relationship of posttreatment decentering and cognitive reactivity to relapse in major depression Journal of Consulting and Clinical Psychology, 2007, 75, 447-455.	1.6	218
329	Response to Dr Moncrieff. Canadian Journal of Psychiatry, 2007, 52, 102-102.	0.9	2
330	Residual Anxiety Symptoms in Depressed Primary Care Patients. Journal of Psychiatric Practice, 2007, 13, 125-128.	0.3	7
331	Sex Differences in Antidepressant Response in a Canadian Primary-Care Sample. Journal of Clinical Psychopharmacology, 2007, 27, 95-98.	0.7	4
332	Medical comorbidity in bipolar disorder: reprioritizing unmet needs. Current Opinion in Psychiatry, 2007, 20, 406-416.	3.1	114
333	Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. Expert Opinion on Pharmacotherapy, 2007, 8, 1615-1628.	0.9	28
334	Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II�. Annals of Clinical Psychiatry, 2007, 19, 257-264.	0.6	215
335	Agomelatine: an antidepressant with a novel mechanism of action. Future Neurology, 2007, 2, 145-151.	0.9	9
336	Are Antidepressants as Effective as Claimed? Yes, but …. Canadian Journal of Psychiatry, 2007, 52, 98-99.	0.9	6
337	Screening for Mental Health Problems among Patients with Substance Use Disorders: Preliminary Findings on the Validation of a Self-Assessment Instrument. Canadian Journal of Psychiatry, 2007, 52, 22-27.	0.9	12
338	Measuring depressive symptoms in the naturalistic primary-care setting. International Journal of Clinical Practice, 2007, 61, 1278-1282.	0.8	2
339	Problem gambling in bipolar disorder: Results from the Canadian Community Health Survey. Journal of Affective Disorders, 2007, 102, 27-34.	2.0	46
340	Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Research - Neuroimaging, 2007, 155, 203-210.	0.9	46
341	Substance Use Disorders and Overweight/Obesity in Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1352-1357.	1.1	65
342	Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatric Disease and Treatment, 2007, 3, 423-8.	1.0	15

#	Article	IF	CITATIONS
343	The effect of antidepressants on lipid homeostasis: a cardiac safety concern?. Expert Opinion on Drug Safety, 2006, 5, 523-537.	1.0	70
344	A review of antidepressant treatments today. European Neuropsychopharmacology, 2006, 16, S619-S623.	0.3	46
345	Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opinion on Pharmacotherapy, 2006, 7, 1305-1321.	0.9	21
346	Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology, 2006, 16, 93-100.	0.3	270
347	Improving outcomes in depression: A focus on somatic symptoms. Journal of Psychosomatic Research, 2006, 60, 279-282.	1.2	46
348	Sexual Function during Bupropion or Paroxetine Treatment of Major Depressive Disorder. Canadian Journal of Psychiatry, 2006, 51, 234-242.	0.9	74
349	Obesity in Bipolar Disorder and Major Depressive Disorder: Results from a National Community Health Survey on Mental Health and Well-Being. Canadian Journal of Psychiatry, 2006, 51, 274-280.	0.9	133
350	Anxiety disorders and bipolar disorder: a review. Bipolar Disorders, 2006, 8, 665-676.	1.1	78
351	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders, 2006, 8, 721-739.	1.1	202
352	The Prevalence and Impact of Migraine Headache in Bipolar Disorder: Results From the Canadian Community Health Survey Headache, 2006, 46, 973-982.	1.8	104
353	Deep brain stimulation for treatment-resistant depression: A psychiatric perspective. Current Psychiatry Reports, 2006, 8, 437-444.	2.1	33
354	Validation of an IVRS version of the MADRS. Journal of Psychiatric Research, 2006, 40, 243-246.	1.5	33
355	Calculated bioavailable testosterone levels and depression in middle-aged men. Psychoneuroendocrinology, 2006, 31, 1029-1035.	1.3	96
356	Cognitive Reactivity to Sad Mood Provocation and the Prediction of Depressive Relapse. Archives of General Psychiatry, 2006, 63, 749.	13.8	383
357	Current treatment options: relief of symptoms and ultimate recovery. International Journal of Psychiatry in Clinical Practice, 2006, 10, 22-26.	1.2	0
358	Medical Comorbidity in Bipolar Disorder: Implications for Functional Outcomes and Health Service Utilization. Psychiatric Services, 2006, 57, 1140-1144.	1.1	164
359	The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opinion on Drug Safety, 2006, 5, 157-168.	1.0	198
360	Treatment guidelines for mania. Journal of Psychiatry and Neuroscience, 2006, 31, 144.	1.4	0

#	Article	IF	CITATIONS
361	Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Journal of Psychiatry and Neuroscience, 2006, 31, 122-31.	1.4	128
362	Clinical translation of neuroimaging research in mood disorders. Psychiatry, 2006, 3, 46-57.	0.3	2
363	Antidepressant Augmentation With Raloxifene. Journal of Clinical Psychopharmacology, 2005, 25, 96-98.	0.7	11
364	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 2005, 7, 5-69.	1.1	321
365	Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps. Canadian Journal of Psychiatry, 2005, 50, 167-174.	0.9	47
366	Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment Implications. Annals of Clinical Psychiatry, 2005, 17, 83-93.	0.6	188
367	Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. Cmaj, 2005, 173, 1327-1334.	0.9	103
368	Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. Cmaj, 2005, 172, 57-59.	0.9	47
369	Deep Brain Stimulation for Treatment-Resistant Depression. Neuron, 2005, 45, 651-660.	3.8	3,560
370	A dimensional approach to personality in atypical depression. Psychiatry Research, 2005, 134, 161-167.	1.7	15
371	Simulator Performance vs. Neurophysiologic Monitoring: Which is More Relevant to Assess Driving Impairment?. , 2005, , .		4
372	The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. Journal of Psychiatry and Neuroscience, 2005, 30, 11-6.	1.4	10
373	Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. Journal of Psychiatry and Neuroscience, 2005, 30, 178-86.	1.4	167
374	Mental Health and Mental Illness In The Workplace: Diagnostic and Treatment Issues. HealthcarePapers, 2004, 5, 54-67.	0.2	17
375	Modulation of Cortical-Limbic Pathways in Major Depression. Archives of General Psychiatry, 2004, 61, 34.	13.8	962
376	The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: An evolutionary perspective. Biological Psychiatry, 2004, 56, 665-669.	0.7	94
377	Childhood Inattention and Dysphoria and Adult Obesity Associated with the Dopamine D4 receptor Gene in Overeating Women with Seasonal Affective Disorder. Neuropsychopharmacology, 2004, 29, 179-186.	2.8	90
378	Limbic–frontal circuitry in major depression: a path modeling metanalysis. NeuroImage, 2004, 22, 409-418.	2.1	674

#	Article	IF	CITATIONS
379	Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology, 2004, 19, 271-280.	0.9	174
380	The 5-Factor Model of Personality and Antidepressant Medication Compliance. Canadian Journal of Psychiatry, 2004, 49, 106-113.	0.9	44
381	Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Canadian Journal of Psychiatry, 2004, 49, 17S-26S.	0.9	23
382	Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disorders, 2003, 5, 28-35.	1.1	103
383	Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disorders, 2003, 5, 36-47.	1.1	100
384	State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge. Biological Psychiatry, 2003, 54, 1274-1283.	0.7	128
385	Dysfunctional Attitudes and 5-HT2Receptors During Depression and Self-Harm. American Journal of Psychiatry, 2003, 160, 90-99.	4.0	254
386	Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opinion on Investigational Drugs, 2003, 12, 65-86.	1.9	27
387	Antipsychotic-Induced Weight Gain: Bipolar Disorder and Leptin. Journal of Clinical Psychopharmacology, 2003, 23, 323-327.	0.7	44
388	A Comparison of Antidepressant Response in Younger and Older Women. Journal of Clinical Psychopharmacology, 2003, 23, 405-407.	0.7	53
389	Lithium Carbonate Versus Cognitive Therapy as Sequential Combination Treatment Strategies in Partial Responders to Antidepressant Medication. Journal of Clinical Psychiatry, 2003, 64, 439-444.	1.1	26
390	Clinical guidelines for depressive disorders. Summary of recommendations relevant to family physicians. Canadian Family Physician, 2003, 49, 489-91.	0.1	10
391	Role of Estrogen in the Treatment of Depression. American Journal of Therapeutics, 2002, 9, 503-509.	0.5	55
392	Antidepressant Side Effects in Depression Patients Treated in a Naturalistic Setting: A Study of Bupropion, Moclobemide, Paroxetine, Sertraline, and Venlafaxine. Canadian Journal of Psychiatry, 2002, 47, 174-180.	0.9	99
393	EEG correlates of acute and chronic paroxetine treatment in depression. Journal of Affective Disorders, 2002, 69, 241-249.	2.0	52
394	Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. Journal of Affective Disorders, 2002, 71, 229-233.	2.0	81
395	Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorders, 2002, 4, 207-213.	1.1	145
396	Combining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine. Journal of Clinical Psychiatry, 2002, 63, 181-186.	1.1	117

#	Article	IF	CITATIONS
397	Combining Antidepressants for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2002, 63, 685-693.	1.1	103
398	Low-dose dexamethasone challenge in women with atypical major depression: pilot study. Journal of Psychiatry and Neuroscience, 2002, 27, 47-51.	1.4	46
399	Full remission: a return to normal functioning. Journal of Psychiatry and Neuroscience, 2002, 27, 233-4.	1.4	19
400	Assessing full remission. Journal of Psychiatry and Neuroscience, 2002, 27, 235-9.	1.4	67
401	Prevalence and outcome of partial remission in depression. Journal of Psychiatry and Neuroscience, 2002, 27, 241-7.	1.4	79
402	Pharmacotherapy to sustain the fully remitted state. Journal of Psychiatry and Neuroscience, 2002, 27, 269-80.	1.4	37
403	Reboxetine: a preliminary report on its use through the Special Access Program. Journal of Psychiatry and Neuroscience, 2002, 27, 418-22.	1.4	4
404	Noradrenergic dysfunction in the prefrontal cortex in depression: an [150] H20 PET study of the neuromodulatory effects of clonidine. Biological Psychiatry, 2001, 49, 317-325.	0.7	34
405	Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. Biological Psychiatry, 2001, 50, 640-643.	0.7	51
406	EEG power, frequency, asymmetry and coherence in male depression. Psychiatry Research - Neuroimaging, 2001, 106, 123-140.	0.9	314
407	Lithium Revisited. Canadian Journal of Psychiatry, 2001, 46, 322-327.	0.9	28
408	Mood-induced changes on the Implicit Association Test in recovered depressed patients Journal of Abnormal Psychology, 2001, 110, 282-289.	2.0	177
409	Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities. Canadian Journal of Psychiatry, 2001, 46, 273-281.	0.9	224
410	Lower dopamine transporter binding potential in striatum during depression. NeuroReport, 2001, 12, 4121-4125.	0.6	242
411	Antidepressants in clinical practice: limitations of assessment methods and drug response. Human Psychopharmacology, 2001, 16, 105-114.	0.7	31
412	Title is missing!. Cognitive Therapy and Research, 2001, 25, 765-779.	1.2	49
413	Comparisons of Men With Full or Partial Eating Disorders, Men Without Eating Disorders, and Women With Eating Disorders in the Community. American Journal of Psychiatry, 2001, 158, 570-574.	4.0	249
414	The Effect of Paroxetine on 5-HT2AReceptors in Depression: An [18F]Setoperone PET Imaging Study. American Journal of Psychiatry, 2001, 158, 78-85.	4.0	222

#	Article	IF	CITATIONS
415	Changes in Regional Brain Glucose Metabolism Measured With Positron Emission Tomography After Paroxetine Treatment of Major Depression. American Journal of Psychiatry, 2001, 158, 899-905.	4.0	624
416	Suicidal Ideation in Major Depression: Sex Differences and Impact of Comorbid Anxiety. Canadian Journal of Psychiatry, 2000, 45, 822-826.	0.9	50
417	Differentiating DSM-IV Anxiety and Depressive Disorders in the General Population: Comorbidity and Treatment Consequences. Canadian Journal of Psychiatry, 2000, 45, 166-172.	0.9	79
418	Determination of paroxetine levels in human plasma using gas chromatography with electron-capture detection. Biomedical Applications, 2000, 749, 275-279.	1.7	22
419	Neurohormonal responses to d-fenfluramine in healthy elderly subjects. A placebo-controlled study. Psychoneuroendocrinology, 2000, 25, 139-150.	1.3	7
420	Pre-Treatment EEG and It's Relationship to Depression Severity and Paroxetine Treatment Outcome. Pharmacopsychiatry, 2000, 33, 201-205.	1.7	115
421	Increased left posterior parietal–temporal cortex activation after d-fenfluramine in women with panic disorder. Psychiatry Research - Neuroimaging, 2000, 98, 133-143.	0.9	31
422	Tolerability and Efficacy of High-Dose Moclobemide Alone and in Combination With Lithium and Trazodone. Journal of Clinical Psychopharmacology, 2000, 20, 394-395.	0.7	3
423	Medication compliance in mood disorders relevance of the Health Belief Model and other determinants. Primary Care and Community Psychiatry, 2000, 6, 101-110.	0.4	21
424	Antidepressant-Induced Sexual Dysfunction During Treatment With Moclobemide, Paroxetine, Sertraline, and Venlafaxine. Journal of Clinical Psychiatry, 2000, 61, 276-281.	1.1	189
425	The effects of single dose nefazodone and paroxetine upon 5-HT 2A binding potential in humans using [18 F]-setoperone PET. Psychopharmacology, 1999, 144, 279-281.	1.5	39
426	A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls. Journal of Affective Disorders, 1999, 52, 121-133.	2.0	14
427	Depression in Ontario: under-treatment and factors related to antidepressant use. Journal of Affective Disorders, 1999, 52, 67-76.	2.0	38
428	Rumination and distraction in major depression: assessing response to pharmacological treatment. Journal of Affective Disorders, 1999, 55, 225-229.	2.0	50
429	Sexual dysfunction before antidepressant therapy in major depression. Journal of Affective Disorders, 1999, 56, 201-208.	2.0	385
430	Clinical aspects of depression. Clinical Cornerstone, 1999, 1, 1-16.	1.0	3
431	Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. , 1999, 25, 187-193.		28

432 Sequencing of cognitive-behavioral treatments for bulimia nervosa. , 1999, 25, 361-374.

55

#	Article	IF	CITATIONS
433	Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry Research, 1999, 86, 211-216.	1.7	41
434	Replicating the five factor model of personality in a psychiatric sample. Personality and Individual Differences, 1999, 27, 1135-1139.	1.6	78
435	Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biological Psychiatry, 1999, 45, 872-882.	0.7	136
436	Title is missing!. Cellular and Molecular Neurobiology, 1999, 19, 411-426.	1.7	50
437	The changing profile of anorexia nervosa at the toronto programme for eating disorders. Journal of Psychosomatic Research, 1998, 45, 533-547.	1.2	10
438	Major Depression in Individuals With a History of Childhood Physical or Sexual Abuse: Relationship to Neurovegetative Features, Mania, and Gender. American Journal of Psychiatry, 1998, 155, 1746-1752.	4.0	166
439	Diminished Serotonin-Mediated Prolactin Responses in Nondepressed Stroke Patients Compared With Healthy Normal Subjects. Stroke, 1998, 29, 1293-1298.	1.0	18
440	Self-Report Ratings and Informants' Ratings of Personalities of Depressed Outpatients. American Journal of Psychiatry, 1998, 155, 437-438.	4.0	73
441	No Effect of Depression on [¹⁵ O]H ₂ O PET Response to Intravenous <i>d</i> -Fenfluramine. American Journal of Psychiatry, 1998, 155, 1241-1246.	4.0	33
442	A randomized controlled trial of guided imagery in bulimia nervosa. Psychological Medicine, 1998, 28, 1347-1357.	2.7	47
443	Hormonal and Subjective Responses to Intravenous m-Chlorophenylpiperazine in Women With Seasonal Affective Disorder. Archives of General Psychiatry, 1998, 55, 244.	13.8	27
444	Reversed neurovegetative symptoms of depression: a community study of Ontario. American Journal of Psychiatry, 1997, 154, 934-940.	4.0	86
445	Depressive symptoms and alterations in sucrose taste perception: Cognitive bias or a true change in sensitivity?. Canadian Journal of Experimental Psychology, 1997, 51, 57-60.	0.7	21
446	A Review of Functional Neuroimaging in Mood Disorders: Positron Emission Tomography and Depression. Canadian Journal of Psychiatry, 1997, 42, 467-475.	0.9	134
447	Personality factors related to the prevalence of somatic symptoms and medical complaints in a healthy student population. The British Journal of Medical Psychology, 1997, 70, 93-101.	0.6	37
448	Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. Biological Psychiatry, 1997, 41, 366-368.	0.7	21
449	Personality and symptom profiles of the angry hostile depressed patient. Journal of Affective Disorders, 1997, 45, 155-160.	2.0	18
450	Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis. Journal of Affective Disorders, 1997, 45, 161-166.	2.0	10

#	Article	IF	CITATIONS
451	Title is missing!. Cognitive Therapy and Research, 1997, 21, 285-300.	1.2	64
452	The effects of moclobemide on sexual desire and function in healthy volunteers. European Neuropsychopharmacology, 1996, 6, 177-181.	0.3	18
453	Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Research, 1996, 63, 219-222.	1.7	113
454	Efficacy and Effectiveness in the Antidepressant Treatment of Depression: Beyond Metaanalysis. Canadian Journal of Psychiatry, 1996, 41, 609-610.	0.9	3
455	Purging and nonpurging forms of bulimia nervosa in a community sample. , 1996, 20, 231-238.		41
456	Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups. American Journal of Psychiatry, 1995, 152, 1052-1058.	4.0	417
457	Assessment of Personality Disorders in Anorexia Nervosa and Bulimia Nervosa A Comparison of Self-Report and Structured Interview Methods. Journal of Nervous and Mental Disease, 1995, 183, 358-364.	0.5	22
458	Views on Classification and Diagnosis of Eating Disorders. Canadian Journal of Psychiatry, 1995, 40, 445-456.	0.9	68
459	Exposure with response prevention treatment of anorexia nervosa-bulimic subtype and bulimia nervosa. Behaviour Research and Therapy, 1995, 33, 685-689.	1.6	21
460	Obsessive compulsiveness and physical activity in anorexia nervosa and high-level exercising. Journal of Psychosomatic Research, 1995, 39, 967-976.	1.2	98
461	The Role of Personality Factors in the Reporting of Side Effect Complaints to Moclobemide and Placebo. Journal of Clinical Psychopharmacology, 1995, 15, 347-352.	0.7	52
462	The role of physical activity in the development and maintenance of eating disorders. Psychological Medicine, 1994, 24, 957-967.	2.7	254
463	Melatonin disturbances in anorexia nervosa and bulimia nervosa. International Journal of Eating Disorders, 1994, 16, 257-265.	2.1	12
464	Therapeutic alliance on an inpatient unit for eating disorders. International Journal of Eating Disorders, 1994, 16, 405-410.	2.1	34
465	The effects of growth hormone-releasing factor on food consumption in anorexia nervosa patients and normals. Biological Psychiatry, 1994, 35, 446-451.	0.7	14
466	Depression in anorexia nervosa and bulimia nervosa: discriminating depressive symptoms and episodes. Journal of Psychosomatic Research, 1994, 38, 773-782.	1.2	71
467	A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. Journal of Affective Disorders, 1994, 32, 105-114.	2.0	14
468	Advances in the Treatment of Anorexia Nervosa and Bulimia Nervosa. CNS Drugs, 1994, 1, 201-212.	2.7	2

#	Article	IF	CITATIONS
469	Changes in perceptions and emotions before and after refeeding in anorexia nervosa: a pilot study. Irish Journal of Psychological Medicine, 1994, 11, 57-63.	0.7	3
470	Factors Complicating the Diagnosis of Depression in Cerebrovascular Disease, Part Ii — Neurological Deficits and Various Assessment Methods [*] . Canadian Journal of Psychiatry, 1994, 39, 601-607.	0.9	14
471	Factors Complicating the Diagnosis of Depression in Cerebrovascular Disease, Part I — Phenomenological and Nosological Issues [*] . Canadian Journal of Psychiatry, 1994, 39, 596-600.	0.9	14
472	Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa. Neurochemical Research, 1993, 18, 1281-1285.	1.6	3
473	The acute effects of starvation on 6-sulphatoxy-melatonin output in subgroups of patients with anorexia nervosa. Psychoneuroendocrinology, 1993, 18, 131-139.	1.3	10
474	The effect of the mao-a selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, 747-763.	2.5	4
475	Advances in Diagnosis and Treatment of Anorexia Nervosa and Bulimia Nervosa*. Canadian Journal of Psychiatry, 1992, 37, 309-315.	0.9	16
476	Correlates of Sexual Abuse in Women with Anorexia Nervosa and Bulimia Nervosa*. Canadian Journal of Psychiatry, 1992, 37, 516-518.	0.9	26
477	Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry Research, 1992, 43, 177-185.	1.7	21
478	Current Perspectives on Drug Therapies for Anorexia Nervosa and Bulimia Nervosa. Drugs, 1991, 41, 367-377.	4.9	26
479	Pineal and adrenal function before and after refeeding in anorexia nervosa. Biological Psychiatry, 1991, 30, 216-224.	0.7	25
480	Post-Residency Fellowship Training. Canadian Journal of Psychiatry, 1991, 36, 151-151.	0.9	1
481	Tryptophan Treatment and Melatonin Response in a Patient with. Journal of Clinical Psychopharmacology, 1991, 11, 74.	0.7	11
482	A Comparison of Adinazolam and Desipramine in the Treatment of Major Depression. International Clinical Psychopharmacology, 1991, 6, 65-76.	0.9	9
483	Graves' disease in a woman with thyroid hormone abuse, bulimia nervosa, and a history of anorexia nervosa. International Journal of Eating Disorders, 1991, 10, 111-115.	2.1	8
484	Mitral valve prolapse in eating and panic disorder: A pilot study. International Journal of Eating Disorders, 1991, 10, 531-537.	2.1	4
485	Self-Report Symptoms That Predict Major Depression in Patients with Prominent Physical Symptoms. International Journal of Psychiatry in Medicine, 1990, 20, 247-258.	0.8	25
486	Sulphatoxy melatonin: An index of depression in anorexia nervosa and bulimia nervosa. Psychiatry Research, 1990, 32, 221-227.	1.7	24

#	Article	IF	CITATIONS
487	Personality disorders in anorexia nervosa and bulimia nervosa. Journal of Psychiatric Research, 1990, 24, 259-269.	1.5	64
488	Changes in Melatonin Levels but Not Cortisol Levels Are Associated With Depression in Patients With Eating Disorders. Archives of General Psychiatry, 1989, 46, 73.	13.8	54
489	Patients admitted to hospital with anorexia nervosa and bulimia nervosa: Psychopathology, weight gain, and attitudes toward treatment. International Journal of Eating Disorders, 1989, 8, 181-190.	2.1	11
490	Cardiac regulation in Bulimia nervosa. Journal of Psychiatric Research, 1989, 23, 267-273.	1.5	22
491	Melatonin and Cortisol "Switches―during Mania, Depression, and Euthymia in a Drug-Free Bipolar Patient. Journal of Nervous and Mental Disease, 1989, 177, 300-303.	0.5	58
492	Clonazepam and Lithium—a Toxic Combination in the Treatment of Mania?. International Clinical Psychopharmacology, 1989, 4, 195-200.	0.9	11
493	Depression in Self-Harm Patients. British Journal of Psychiatry, 1989, 154, 41-47.	1.7	43
494	The Clinician-Investigator Interface in Psychiatry: I — Values and Problems. Canadian Journal of Psychiatry, 1989, 34, 361-363.	0.9	12
495	Measured Weight Loss and the Dexamethasone Suppression Test*. Canadian Journal of Psychiatry, 1989, 34, 707-709.	0.9	2
496	The Clinician-Investigator Interface in Psychiatry: II - The Role of the Clinical Investigation Unit. Canadian Journal of Psychiatry, 1989, 34, 364-368.	0.9	7
497	Pharmacological Management of Refractory Depression. Canadian Journal of Psychiatry, 1989, 34, 451-456.	0.9	6
498	Psychiatry in Canada. Psychiatric Bulletin, 1989, 13, 370-372.	0.3	0
499	Personality disorders in anorexic patients. International Journal of Eating Disorders, 1988, 7, 589-599.	2.1	96
500	A Trial of Isocarboxazid in the Treatment of Bulimia Nervosa. Journal of Clinical Psychopharmacology, 1988, 8, 391???396.	0.7	66
501	The diagnosis of major depression in renal dialysis patients Psychosomatic Medicine, 1987, 49, 482-492.	1.3	120
502	The Dexamethasone Suppression Test and Suicidal Patients. British Journal of Psychiatry, 1985, 147, 419-423.	1.7	14
503	Monoamine Oxidase Inhibitor Therapy for Anorexia Nervosa and Bulimia: A Preliminary Trial of Isocarboxazid. Journal of Clinical Psychopharmacology, 1985, 5, 279-285.	0.7	32
504	Risk Factors for Depression in Canadians. Canadian Journal of Psychiatry, 1984, 29, 11-13.	0.9	2

#	Article	IF	CITATIONS
505	Depression in Chronic Schizophrenia. British Journal of Psychiatry, 1983, 142, 465-470.	1.7	106
506	Life Events Precipitating Mania. British Journal of Psychiatry, 1983, 142, 398-403.	1.7	120